Susquehanna International Group
HRTX icon

Susquehanna International Group’s Heron Therapeutics HRTX Stock Holding History

Susquehanna International Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.7K Buy
+58,400
New +$67.7K ﹤0.01% 12654
2025
Q3 		– Sell
-15,300
Closed -$31.7K – 13039
2025
Q2 		$31.7K Sell
15,300
-410,100
-96% -$837K ﹤0.01% 12236
2025
Q1 		$936K Sell
425,400
-1,516,700
-78% -$2.94M ﹤0.01% 7423
2024
Q4 		$2.97M Buy
1,942,100
+1,901,900
+4,731% +$3.08M ﹤0.01% 4495
2024
Q3 		$80K Buy
40,200
+1,900
+5% +$4.54K ﹤0.01% 11173
2024
Q2 		$134K Sell
38,300
-80,400
-68% -$247K ﹤0.01% 10807
2024
Q1 		$329K Sell
118,700
-15,500
-12% -$39K ﹤0.01% 9507
2023
Q4 		$228K Buy
+134,200
New +$148K ﹤0.01% 10406
2023
Q1 		– Sell
-18,300
Closed -$45.8K – 12960
2022
Q4 		$45.8K Sell
18,300
-14,100
-44% -$45.4K ﹤0.01% 11441
2022
Q3 		$137K Buy
32,400
+14,200
+78% +$55.6K ﹤0.01% 11362
2022
Q2 		$51K Sell
18,200
-83,900
-82% -$337K ﹤0.01% 11964
2022
Q1 		$584K Buy
+102,100
New +$747K ﹤0.01% 8576
2021
Q4 		– Sell
-15,900
Closed -$170K – 13439
2021
Q3 		$170K Buy
+15,900
New +$194K ﹤0.01% 11667
2021
Q2 		– Sell
-163,900
Closed -$2.66M – 12843
2021
Q1 		$2.66M Buy
+163,900
New +$2.92M ﹤0.01% 5237
2020
Q2 		– Sell
-27,600
Closed -$324K – 10443
2020
Q1 		$324K Sell
27,600
-48,500
-64% -$912K ﹤0.01% 7828
2019
Q4 		$1.79M Buy
76,100
+10,400
+16% +$230K ﹤0.01% 4517
2019
Q3 		$1.22M Sell
65,700
-47,800
-42% -$880K ﹤0.01% 5277
2019
Q2 		$2.11M Sell
113,500
-547,100
-83% -$10.9M ﹤0.01% 4071
2019
Q1 		$16.1M Buy
660,600
+558,100
+544% +$14.6M 0.01% 1346
2018
Q4 		$2.66M Buy
102,500
+23,800
+30% +$654K ﹤0.01% 3094
2018
Q3 		$2.49M Sell
78,700
-129,800
-62% -$4.83M ﹤0.01% 3645
2018
Q2 		$8.1M Sell
208,500
-195,200
-48% -$6.21M ﹤0.01% 2159
2018
Q1 		$11.1M Buy
403,700
+283,000
+234% +$6.42M ﹤0.01% 1682
2017
Q4 		$2.19M Buy
120,700
+58,700
+95% +$957K ﹤0.01% 3749
2017
Q3 		$1M Sell
62,000
-54,800
-47% -$860K ﹤0.01% 5266
2017
Q2 		$1.62M Buy
116,800
+78,600
+206% +$1.14M ﹤0.01% 4301
2017
Q1 		$573K Sell
38,200
-442,500
-92% -$6.12M ﹤0.01% 6242
2016
Q4 		$6.3M Buy
480,700
+158,500
+49% +$2.49M ﹤0.01% 2078
2016
Q3 		$5.55M Buy
322,200
+46,600
+17% +$865K ﹤0.01% 2115
2016
Q2 		$4.97M Buy
275,600
+154,300
+127% +$3.01M ﹤0.01% 2206
2016
Q1 		$2.3M Sell
121,300
-191,600
-61% -$3.78M ﹤0.01% 3509
2015
Q4 		$8.35M Sell
312,900
-529,100
-63% -$14.1M ﹤0.01% 1936
2015
Q3 		$20.5M Buy
842,000
+615,800
+272% +$20.5M 0.01% 1181
2015
Q2 		$7.05M Sell
226,200
-205,000
-48% -$3.86M ﹤0.01% 2444
2015
Q1 		$6.27M Buy
+431,200
New +$4.86M ﹤0.01% 2425

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Susquehanna International Group's HRTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Heron Therapeutics (HRTX) stake by 15% in Q1 2026, selling an estimated $60.2K and leaving 288,253 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11431.

Susquehanna International Group first reported a position in HRTX in Q2 2014 and has held it in 46 quarters since. The position peaked at $27.8M in Q2 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Susquehanna International Group held 288,253 shares of Heron Therapeutics worth $231K as of Q1 2026.
  • Susquehanna International Group sold 51,993 Heron Therapeutics shares in Q1 2026, an estimated $60.2K.
  • Heron Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11431 holding.
  • Susquehanna International Group first reported a position in Heron Therapeutics in Q2 2014 and has held it in 46 quarters since.
  • Susquehanna International Group's Heron Therapeutics position peaked at $27.8M in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.